← Career intelligence
Free · no sign-up · 3,138 priced deals

The deal tape

A precedent transactions set answers one question: what did somebody actually pay for a company like this one. Every row here is a US public target that filed a merger proxy or a going-private statement since 2020, with the offer per share, the premium to the unaffected price and the enterprise value multiples read from the filing itself rather than bought from a feed. Choose a sector, an industry code and a size band, and the quartiles above the list are the answer for that cut.

What it is not. Private-company deals, non-US targets and any transaction where no proxy was required leave nothing to read, so none of them are here. Neither are minority stakes or asset sales. Where a cross-check failed, the row still appears and says why, and it is held out of every median and quartile so one bad reading cannot move a number you would quote.

What this cut was bought at

Each measure counts the readings that survive its own cross-checks. Fewer than 4 is a coincidence, not a market.

MeasureDeals25thMedian75th
EV / LTM EBITDA8658.0x12.7x19.5x
EV / LTM revenue12700.7x1.6x3.5x
Premium to unaffected price115920%32%52%
Premium to 30-day VWAP22116%34%48%

Read the EBITDA multiple against the revenue multiple before you use either. Where they disagree sharply the target was priced on growth rather than earnings, and the EBITDA line is the one that will not survive a second question.

Deals by year of announcement
0901792009: 11 deals, 2 clean on every measure2009112010: 179 deals, 40 clean on every measure20101792011: 164 deals, 92 clean on every measure20111642012: 133 deals, 117 clean on every measure20121332013: 155 deals, 136 clean on every measure20131552014: 98 deals, 85 clean on every measure2014982015: 121 deals, 108 clean on every measure20151212016: 156 deals, 142 clean on every measure20161562017: 120 deals, 109 clean on every measure20171202018: 127 deals, 113 clean on every measure20181272019: 115 deals, 108 clean on every measure20191152020: 87 deals, 73 clean on every measure2020872021: 119 deals, 99 clean on every measure20211192022: 112 deals, 98 clean on every measure20221122023: 108 deals, 86 clean on every measure20231082024: 133 deals, 109 clean on every measure20241332025: 121 deals, 98 clean on every measure20251212026: 62 deals, 52 clean on every measure202662
Clean on every measure In doubt on one measure or both
Median EV / LTM EBITDA by sector
Healthcare: 18.4x median across 84 dealsHealthcare18.4xn=84Technology: 16.7x median across 170 dealsTechnology16.7xn=170Real Estate: 16.2x median across 51 dealsReal Estate16.2xn=51Business Services: 12.8x median across 74 dealsBusiness Services12.8xn=74Industrials: 12.7x median across 116 dealsIndustrials12.7xn=116Financials: 12.7x median across 25 dealsFinancials12.7xn=25Utilities: 12.1x median across 58 dealsUtilities12.1xn=58Consumer & Retail: 10.3x median across 141 dealsConsumer & Retail10.3xn=141Materials: 9.6x median across 40 dealsMaterials9.6xn=40Other: 9.5x median across 31 dealsOther9.5xn=31Media & Telecom: 9.3x median across 41 dealsMedia & Telecom9.3xn=41Energy: 8.5x median across 34 dealsEnergy8.5xn=34
Deals by sector
Technology: 421 dealsTechnology421Healthcare: 315 dealsHealthcare315Consumer & Retail: 245 dealsConsumer & Retail245Industrials: 234 dealsIndustrials234Financials: 216 dealsFinancials216Business Services: 155 dealsBusiness Services155Real Estate: 142 dealsReal Estate142Media & Telecom: 85 dealsMedia & Telecom85Energy: 82 dealsEnergy82Utilities: 79 dealsUtilities79Materials: 78 dealsMaterials78Other: 69 dealsOther69
Deals by buyer type
Financial sponsor: 123 dealsFinancial sponsor123Strategic: 1073 dealsStrategic1073Management / founder: 2 dealsManagement / founder2Controlling holder: 10 dealsControlling holder10Acquisition vehicle: 0 dealsAcquisition vehicle0Unclassified: 913 dealsUnclassified913
Deals by enterprise value
Under $250m: 809 dealsUnder $250m809$250m to $1bn: 489 deals$250m to $1bn489$1bn to $5bn: 538 deals$1bn to $5bn538$5bn to $20bn: 211 deals$5bn to $20bn211Over $20bn: 31 dealsOver $20bn31Not computed: 43 dealsNot computed43
Deals by industry code
Business Services & Software: 390 dealsBusiness Services & Sof…390Chemicals, Pharmaceuticals & Allied Products: 204 dealsChemicals, Pharmaceutic…204Electronics & Electrical Equipment: 149 dealsElectronics & Electrica…149Instruments, Medical Devices & Optical Goods: 109 dealsInstruments, Medical De…109Holding & Other Investment Offices: 96 dealsHolding & Other Investm…96Electric, Gas & Sanitary Services: 79 dealsElectric, Gas & Sanitar…79Insurance Carriers: 72 dealsInsurance Carriers72Industrial Machinery & Computers: 69 dealsIndustrial Machinery & …69Health Services: 69 dealsHealth Services69Communications: 65 dealsCommunications65
TargetAcquirerIndustryEVEV / EBITDAEV / revenuePremiumFiling
Aerojet Rocketdyne Holdings, Inc.
2022-12-17 · Public merger · $58.00 a share
L3Harris Technologies, Inc.
Strategic
Industrials$4.6bn18.6x2.1x
n.a.
DEFM14A
All cash
Trean Insurance Group, Inc.
2022-12-15 · Take-private · $6.15 a share
Board book on file →
Altaris Constellation Partners, L.P.
Financial sponsor
Financials$311mn.a.35.8x
95%
80% to VWAP
SC 13E3
All cash
Maxar Technologies Inc.
2022-12-15 · Public merger · $53.00 a share
Galileo Parent, Inc.
Unclassified
Technology$6.1bn13.3x3.5x
129%
DEFM14A
All cash
Coupa Software Inc
2022-12-11 · Public merger · $81.00 a share
Not named in the filing
Unclassified
Technology$5.3bnn.a.6.5x
25%
DEFM14A
All cash
Weber Inc.
2022-12-11 · Take-private · $8.05 a share
Board book on file →
BDT & MSD Holdings, L.P.
Financial sponsor
Technology$1.8bnn.a.1.1x
60%
SC 13E3
All cash
Apollo Endosurgery, Inc.
2022-11-29 · Public merger · $10.00 a share
Boston Scientific
Strategic
Healthcare$383mn.a.5.3x
67%
DEFM14A
All cash
AgroFresh Solutions, Inc.
2022-11-21 · Take-private · $3.00 a share
Held out of the multiples: EV / LTM EBITDA 77.5x outside 1x to 75x
Board book on file →
Not named in the filing
Financial sponsor
Materials$380m77.5x2.2x
79%
SC 13E3
All cash
Opiant Pharmaceuticals, Inc.
2022-11-13 · Public merger · $20.00 a share
Indivior Inc.
Strategic
Healthcare$80mn.a.3.6x
111%
DEFM14A
All cash
Verde Clean Fuels, Inc.
2022-11-10 (filed) · Public merger · $10.00 a share
Not named in the filing
Unclassified
Materials$218mn.a.n.a.
n.a.
DEFM14A
All cash
Wheeler Real Estate Investment Trust, Inc.
2022-11-01 (filed) · Take-private · $15.50 a share
Held out of the multiples: EV / LTM revenue 850.0x above 60x
Not named in the filing
Unclassified
Real Estate$595mn.a.850.0x
n.a.
SC 13E3
All cash
Benefitfocus, Inc.
2022-11-01 · Public merger · $10.50 a share
Voya Financial, Inc.
Strategic
Technology$310m20.1x1.2x
67%
DEFM14A
All cash
Atlas Corp.
2022-10-31 · Take-private · $15.50 a share
Held out of the multiples: equity value 3,829 vs fee-table value 1
Board book on file →
Not named in the filing
Strategic
Industrials$7.8bn6.9x4.8x
34%
8% to VWAP
SC 13E3
All cash
Appreciate Holdings, Inc.
2022-10-28 (filed) · Public merger · $1.50 a share
Not named in the filing
Unclassified
Real Estate$9mn.a.n.a.
n.a.
DEFM14A
All cash
Altra Industrial Motion Corp.
2022-10-26 · Public merger · $62.00 a share
Regal Rexnord Corporation
Strategic
Industrials$4.9bn25.0x2.5x
66%
73% to VWAP
DEFM14A
All cash
UserTesting, Inc.
2022-10-26 · Public merger · $7.50 a share
Thunder Holdings, LLC, Inc.
Strategic
Technology$921mn.a.n.a.
95%
DEFM14A
All cash
Myovant Sciences Ltd.
2022-10-23 · Take-private · $27.00 a share
Board book on file →
Sumitomo Pharma Co., LTD.
Strategic
Healthcare$2.2bnn.a.6.7x
50%
48% to VWAP
SC 13E3
All cash
Continental Resources, Inc
2022-10-16 · Take-private · $74.28 a share
Board book on file →
Omega Acquisition, Inc.
Strategic
Energy$31bn4.6x3.6x
n.a.
9% to VWAP
SC 13E3
All cash
EUDA Health Holdings Ltd
2022-10-13 (filed) · Public merger · $10.00 a share
Not named in the filing
Unclassified
Healthcare$111mn.a.10.5x
n.a.
DEFM14A
All cash
Albertsons Companies, Inc.
2022-10-13 · Public merger · $34.10 a share
The Kroger Co.
Strategic
Consumer & Retail$23bn5.3x0.3x
33%
30% to VWAP
DEFM14C
All cash
KnowBe4, Inc.
2022-10-11 · Take-private · $24.90 a share
Board book on file →
Elephant Partners 2019 Spv-a, L.P.
Financial sponsor
Technology$2.1bn64.7x6.7x
44%
SC 13E3
All cash
ForgeRock, Inc.
2022-10-10 · Public merger · $23.25 a share
Not named in the filing
Unclassified
Technology$774mn.a.3.8x
53%
DEFM14A
All cash
Industrias Bachoco S.A.B. de C.V.
2022-10-06 (filed) · Take-private · $81.66 a share
Held out of the multiples: no balance sheet at announcement: EV = equity value; equity value 48,996 vs fee-table value 649
Not named in the filing
Controlling holder
Consumer & Retail$49bnn.a.n.a.
23%
SC 13E3
All cash
Poshmark, Inc.
2022-10-03 · Public merger · $17.90 a share
Proton Parent
Unclassified
Consumer & Retail$389mn.a.1.1x
n.a.
DEFM14A
All cash
Coeptis Therapeutics Inc.
2022-09-30 (filed) · Public merger · $10.00 a share
Bull Horn Holdings Corp.
Strategic
Healthcare$383mn.a.n.a.
n.a.
DEFM14A
All cash
O2micro International Ltd
2022-09-30 · Take-private · $0.10 a share
Board book on file →
Fnof Dynamic Holdings LTD
Strategic
Technology$93m5.7x0.9x
69%
SC 13E3
All cash

How to use a set like this

Cut to the narrowest set that still holds eight or ten deals, then quote the range rather than the median. An interviewer who asks where software takes out will accept a spread and press on a single number, because the single number implies a precision the set does not have. Say which deals sit at each end and why: the top of a range is usually a contested auction or a strategic buyer with synergies, the bottom a controlling holder buying in the minority.

Premiums move with the reference price, not only with the deal. A bidder quotes the period that flatters the offer, so read the premium to the unaffected close beside the premium to the thirty-day average and notice when they diverge.

What each column means

Enterprise value.
Offer per share times shares outstanding, plus net debt at the last balance sheet before the merger agreement. It is blank where either piece was missing, and those rows are in the “not computed” band rather than in a size they never earned.
Premium.
The offer against the unaffected price, which is the last close before the deal became known. Where the filing states a premium to the thirty-day volume-weighted average, that is shown next to it.
Deal type.
A take-private is bought by an affiliate, which is what triggers the Schedule 13E-3 and the fuller disclosure that comes with it. A public merger is an arm’s-length buyer, disclosed through the merger proxy.
In doubt.
A cross-check the reading could not satisfy: an equity value far from the fee-table figure, a multiple outside any sane band, or consideration that is partly stock so the per-share cash figure is not the price. The row stays visible, and it is set aside only for the measures the doubt reaches. A cash-and-stock deal cannot price a multiple and still states a premium the filing itself computed, so it counts in one and not the other.

Company names, tickers and logos are the trademarks of their respective owners and appear here to identify the company whose public figures are being used. L3VLUP is not affiliated with, sponsored by or endorsed by any company shown, and nothing here is a statement by or about that company. More